AP26113
- CAS NO.:1197958-12-5
- Empirical Formula: C26H34ClN6O2P
- Molecular Weight: 529.01
- MDL number: MFCD23704187
- EINECS: 234-394-2
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-09-22 21:01:39
What is AP26113?
The Uses of AP26113
AP 26113 is a potent anaplastic lymphoma kinase (ALK) inhibitor. It is also an epidermal growth factor (EGFR) receptor tyrosine kinase inhibitor used for treatment of lung cancer.
Biological Activity
ap26113 is a novel, synthetic, orally available small-molecule inhibitor of anaplastic lymphoma kinase (alk), which is a receptor tyrosine kinase in the insulin receptor superfamily, with half maximal inhibitory concentration ic50 ranging from 5 nmol/l to 11 nmol/l. ap26113 is also capable of inhibiting the alk tyrosine kinase gatekeeper mutation l1196m (ic50: 15 nmol/l to 45 nmol/l), mutant epidermal growth factor receptor (egfr) containing the gatekeeper t790m mutation and c-ros oncogene 1 (ros1). moreover, ap26113 has been found to be active against h3122 cells (both sensitive and resistant) and ba/f3 cells harboring native or mutant eml4-alk (ic50: 10 nm and 24 nm respectively).
Enzyme inhibitor
This potent ALK inhibitor (FW = 529.02 g/mol; CAS 1197958-12-5; Solubility: 45 mg/mL DMSO; <1 mg/mL H2O), also named 5-chloro-N2-[4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl]-N4-[2-(dimethyl- phosphinyl)phenyl]-2,4-pyrimidinediamine, inhibits wild type Lymphoma Kinase, or ALK (Ki = 0.62 nM) and overcomes crizotinib resistance in non- small cell lung cancers harboring the fusion oncogene EML4-ALK. Cells often develop the L1196M gatekeeper mutation within the kinase domain, a changes that renders them resistant to crizotinib, even at higher drug doses (1 μM). AP26113 is highly active against these resistant cancer cells, both in vitro and in vivo.
References
[1]solomon b, wilner kd, shaw at. current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. clin pharmacol ther. 2014 jan;95(1):15-23. doi: 10.1038/clpt.2013.200. epub 2013 oct 3.
[2]katayama r1, khan tm, benes c, lifshits e, ebi h, rivera vm, shakespeare wc, iafrate aj, engelman ja, shaw at. therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene eml4-alk. proc natl acad sci u s a. 2011 may 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. epub 2011 apr 18.
Properties of AP26113
Boiling point: | 737.6±70.0 °C(Predicted) |
Density | 1.29±0.1 g/cm3(Predicted) |
storage temp. | Store at -20°C |
solubility | ≥26.45 mg/mL in DMSO; insoluble in H2O; ≥55.9 mg/mL in EtOH |
form | solid |
pka | 9.27±0.20(Predicted) |
color | White to off-white |
CAS DataBase Reference | 1197958-12-5 |
Safety information for AP26113
Signal word | Warning |
Pictogram(s) |
Exclamation Mark Irritant GHS07 |
GHS Hazard Statements |
H302:Acute toxicity,oral H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for AP26113
New Products
ALUMINIUM IODIDE 100 GM BUFFER CAPSULE PH 7.0 - 10 CAP BUFFER SOLUTION PH 9.5 (BORATE) EZEE BLUE GEL STAINER BORAX CARMINE (GRENACHERS ALCOHOLIC) POTASSIUM IODATE - IODIDE SOLN 0.1 N Dabigatran Acyl-O3-D-Glucuronide Trifluoroacetic Acid Salt Isofolic Acid Dabigatran 2-O-acylglucuronide metabolite Dabigatran Acyl-?-D- glucuronide Trifluroacetic Acid Erythromycin EP Impurity A Desloratidine Related Compound ARelated products of tetrahydrofuran
You may like
-
Ap26113 95% CAS 1197958-12-5View Details
1197958-12-5 -
Dechloro DesloratadineView Details
-
Dehydro DesloratadineView Details
-
Edoxaban Impurity 57View Details
2089454-69-1 -
Eltrombopag N-Oxide ImpurityView Details
2734533-17-4 -
Empagliflozin Bromo ImpurityView Details
-
Glycopyrronium Bromide EP Impurity IView Details
1404617-94-2 -
Ipratropium EP Impurity BView Details
58073-59-9